Merck Receives FDA Approval for KEYTRUDA Combination Therapy in Renal Cell Carcinoma and Announces Acquisition of Targan
On June 12, 2026, Merck (MRK) announced that the U.S. Food and Drug Administration approved its combination therapy involving KEYTRUDA and WELIREG for adjuvant treatment in renal cell carcinoma patients at high risk of recurrence. Additionally, on June 11, 2026, Merck Animal Health signed an agreement to acquire Targan, a poultry biodevice developer.
Tickers: $MRK